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Abstract 
Objective: To evaluate long-term outcomes in patients maintaining a nevirapine (NVP)-based regimen.  
Methods: Retrospective, multicenter, cohort study including patients currently receiving an NVP regimen that had 
been started at least 5 years previously. Demographic, clinical, and analytical variables were recorded.  
Results: Median follow-up was 8.9 (5.7-11.3) years. Baseline characteristics: 74% men, 47 years old, 36% drug users, 
40% AIDS, 40% HCV+, 51.4% detectable HIV-1 viral load, CD4 count 395 (4-1,421)/μL, 19% CD4 <200/μL, 27% 
ALT grade 1-2, 36% AST grade 1-2. Thirty percent ART-naive, 83% received NVP associated with 2 nucleoside 
analogues during the study period, and 17% a protease inhibitor.  
A significant improvement was observed in general health status markers, including hemoglobin, platelets, and 
albumin, regardless of HCV coinfection. CD4 cell gain was +218 and +322/μL after 6 and 9 years, respectively (+321 
and +391 in naive patients). Triglycerides significantly decreased in pretreated patients, whereas the percentage of 
patients with HDLc <1.03 mmol/L and LDL-c >3.37 mmol/L significantly decreased in a subsample with available 
values. A significant decrease in transaminases, alkaline phosphatase, and Fib4 score was observed, mainly in HCV+ 
and ARV-naive patients.  
Conclusions: In patients who tolerate NVP therapy, (even those with HCV coinfection), long term benefits may be 
significant in terms of a progressive improvement in general health status markers and CD4 response, a favorable 
lipid profile, and good liver tolerability. 
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Combined antiretroviral therapy (cART) is the standard of care for HIV-infected patients. Among 
antiretroviral (ARV) regimens, a nucleoside backbone associated with a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) is considered a first-line option in ART-naïve patients [1]. The NNRTI 
nevirapine (NVP) is one of the “oldest” currently available ARV drugs, first commercialized in 1997. 
Despite the development of many new ARV compounds since then, NVP is still considered a first option 
in European Guidelines [1] and an acceptable option in US guidelines [2], and continues to be prescribed 
in a considerable number of patients. One of the main advantages of NVP regimens is their lipid profile 
[3, 4], whereas hypersensitivity and liver toxicity are considered limitations [5].  
 
Most clinical trials evaluating ARV regimens have a follow-up of one or two years. Longer 
experiences come from observational cohort studies or routine clinical practice. Although cART has been 
prescribed for about 15 years, there is little long-term published information regarding ARV regimens [6, 
7].  
 
HIV infection has become a chronic disease and patients need treatment for many years; hence, it is 
important to know the long-term tolerability of ARV regimens. The objective of this study was to assess 
the general health status, liver function, lipid changes, and CD4 counts of patients receiving NVP for at 
least five years. To our knowledge, this study contains the longest clinical follow-up data related to the 
use of NVP-containing regimens.  
METHODS  
This is a retrospective, observational, multicenter cohort study, including adult HIV-infected patients 
currently receiving a NVP-containing regimen that had been started more than 5 years previously. 
Patients initiating a nevirapine-containing regimen between January 1
st
 1998 and June 30
th
 2003 and 
continuing with nevirapine up to the end of July 2008, were included in the study. In centres where the 
number of patients still on nevirapine was greater than 30, we selected a random sample of 30 patients in 
each of them. Randomization was done centrally by computergenerated random numbers. The final 
sample size obtained (506 patients) was considered large enough to estimate the pre-defined end points. 
 
The primary end points were liver, lipid, and CD4 outcomes. Baseline demographic information was 
documented, and the following data were recorded for yearly analysis: CD4 count, viral load, blood cells, 
and ALT, AST, alkaline phosphatase, GGT, glucose, creatinine, total cholesterol, triglycerides, HDL-c, 
and LDL-c levels. Data assessing liver fibrosis, such as FibroScan and liver biopsy, were recorded when 
available, and the Fib-4 test was determined using the formula: (age x AST) / (Platelets x square root of 
ALT) [8].  
Statistical Analysis  
Results for continuous variables are presented as the median of the absolute values or as the median 
percentage change from baseline and the range (minimum and maximum). Results for categorical 
variables are presented as frequencies and percentages. Between-group comparisons of continuous 
variables were performed with the independent t-test for those with a normal distribution and the Mann 
Whitney U test for those with a non-normal distribution. Comparisons between follow-up and baseline 
results of continuous variables were carried out with the t-test for repeated measures in those with a 
normal distribution and Wilcoxon’s signed-rank test in those with a non-normal distribution. A two-sided 
significance level of 0.05 was used in all comparisons. Analyses were performed with PASW Statistics, 
version 18.0.0 (SPSS, Inc., 2009, Chicago, IL, www.spss.com).  
  
RESULTS  
Baseline Characteristics  
5521 patients initiated a nevirapine-containing regimen in the period 1998-2003 in the participating 
hospitals, and 1394 of them (25.2%) remained taking nevirapine at the study enrollment (2008). After 
randomization, 506 patients were included in the study.  
 
Baseline characteristics are shown in Table 1. Patients had been followed-up for a median of 8.9 (5.7-
11.3) years: 270 (53.3%) had been followed-up for 9 years and 506 (100%) for 6 years. More than 95% of 
patients were white, native Spaniards: 26% were women, 36% drug users, 40% had AIDS, and 44% had 
HCV (40.1%) or HBV (4%) coinfection. Among coinfected patients, 61 (27.6%) received therapy for 
chronic HCV/HBV, and 37 (16.7%) presented a sustained virologic response. Median CD4 count was 395 
(4- 1421 cells/μL), and HIV-1 viral load (VL) was <40 (<40- 831,250) copies/mL; 18.8% of patients had 
a CD4 count <200 cells/μL and 54.5% had an undetectable HIV-1 VL. Thirty percent of patients were 
ART-naïve when initiating NVP and 69.9% were ART-experienced. Of the 51.4% (n=253) of patients 
initiating nevirapine with a detectable viral load at baseline, 102 were pretreated patients with previous 
virologic failure or discontinuation of prior therapies due to toxicities (20.2% of the total). The current 
regimens most frequently used were: tenofovir/emtricitabine/ NVP in 31.2%, abacavir/lamivudine/NVP 
in 23.7%, and zidovudine/lamivudine/NVP in 22.3%. Protease inhibitors (PI) –mainly indinavir and 
nelfinavir- were associated in 17.4% (all except 4 patients had been pretreated) whereas nucleoside 
analogues alone were combined with NVP in 83.6%. At the end of follow-up, only 2.9 % of patients 
maintained the PI (mainly lopinavir/ritonavir).  
 
Among the total, 27.6% of patients presented ALT levels above the normal range (26.6% grade 1-2 
and 1% grade 3), and 37.7% had AST above normal range (36.1% and 1.6%, respectively).  
  
Table 1. Baseline Characteristics and Laboratory Parameters 
  N Mean Median Min-Max 
      
Age   506 48.7 47.0 26.0-85.0 
Follow-up time (years)   506 8.5 8.9 5.7-11.3 
    N % 
Sex 
Males    374 73.9 
Females    132 26.1 
Risk practice 
Heterosexuals    178 35.2 
Homosexuals    130 25.7 
Intravenous drug users    182 36.0 
Other    16 3.2 
Race 
White    492 97.2 
Other    14 2.8 
Country of origin 
Spain    484 95.7 
Other   22 4.3 
AIDS     205 40.5 
Naive at NVP initiation     151 29.8 
HBV     20 4.0 
HCV*     203 40.1 
Substance abuse  
Alcohol   70 13.8 
Drugs 
 Former 183 36.2 
  Current 11 2.2 
      
  N Mean Median Min-Max 
      
Hemoglobin (g/L)   478 142.4 143.0 83.0-180.0 
Platelets (x109/L)   477 206.3 204.0 17.9-698.0 
Albumin (g/L)   233 43.9 44.7 13.0-60.0 
VL (copies/mL)   486 28711.0 39.0 23-831250 
CD4 count   490 441.5 395.0 4-1421 
ALT (μkat/L)   489 0.75 0.50 0.13-5.15 
AST (μkat/L)   443 0.69 0.48 0.17-4.87 
    N % 
Detectable VL     253 51.4 
CD4 count <200     92 18.8 
ALT Toxicity 
Grade I- II N (%)    130 26.6 
Grade III N (%)    5 1.0 
AST Toxicity 
Grade I- II N (%)    160 36.1 
Grade III N (%)    7 1.6 
      
  N Mean Median Min-Max 
      
Bilirubin T (μmol/L)   405 11.95 8.89 1.71-81.57 
GGT (μkat/L)   442 1.16 0.59 0.08-18.00 
AP (μkat/L)   466 2.68 2.55 0.40-21.80 
TG (mmol/L)   384 2.46 1.67 0.38-36.59 
TC (mmol/L)   412 5.32 5.15 1.73-12.83 
HDL-c (mmol/L)   101 1.19 1.07 0.52-8.97 
LDL-c (mmol/L)   98 3.79 3.45 1.11-9.44 
Creatinine (μmol/L)   425 84.97 83.98 17.7-194.5 
      
 
203 patients had HIV/HCV coinfection and a liver biopsy or FibroScan was performed in 83 (49%); 47 (56%) of them had 
significant fibrosis (Metavir Score >2 or FibroScan >7kPa). 
AP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GGT, gamma-glutamyltransferase; T, total; TC, 
total cholesterol; TG, triglycerides; VL, viral load. 
Grade I-II ALT: > ULN - 5 x ULN, Grade III-IV ALT: > 5.0 x ULN. 
Grade I-II AST: > ULN - 5 x ULN, Grade III-IV AST: > 5.0 x ULN. 




General Health Status  
Changes in hemoglobin levels, albumin levels, and platelet counts (Fig. 1): Hemoglobin levels 
significantly increased after 6 and 9 years of follow-up (5 g/L (3.34%), p<0.001; and 7 g/L (4.76%), 
p<0.001) regardless of HCV coinfection (HCV+ p<0.001 at 6 and 9 years, HCV- p<0.001 at 6 and 9 
years), although the increase was significantly greater in naïve patients at 6 years (6g/L vs 4g/L, p=0.014). 
Platelet counts were significantly higher in pretreated patients compared to naïve patients (214,000 vs 
190,000/μL, p<0.001). However, platelet increase was significantly greater after 6 and 9 years in ART-
naïve patients (39,000 [19.6%] and 34,000 [17.6%]) versus pretreated patients (3,000 [1.5%] and 12,000 
[7.1%]) (both time points, p<0.001) (Fig. 2). Platelet count significantly increased in both HCV+ and 
HCV- patients, with no differences between these groups. Similarly, albumin levels significantly 
increased regardless of HCV coinfection. Changes in general health status parameters were similar, 









Fig. (2). Percentage change in laboratory parameters in naïve versus pretreated patients. 
CD4 Count and Viral Load 
In the overall cohort, CD4 count significantly increased at 6 and 9 years: +210 cells/μL and +296 
cells/μL, respectively (both, p<0.001). In patients treated with 2 nucleoside analogues + NVP, results 
were very similar: +218 cells/μL and +322 cells/μL. The increase was greater in patients who did not 
have HCV coinfection (+257 vs +176 cells/μL at 6 years, p=0.007) (Fig. 3), and results were similar in 
those who were not receiving a PI. ART-naïve patients had lower baseline CD4 counts than pretreated 
patients (p<0.001) but no differences were observed after 6 and 9 years of follow-up because of a greater 
CD4 gain in naïve patients: +321 vs +168 cells/μL (p<0.001) at 6 years and +391 vs +250 cells/μL 
(p<0.001) at 9 years (Fig. 2). While 51.4% of patients had detectable plasma HIV-1 viral load at baseline, 
viral load was undetectable in 96.7% patients (n= 487) after 6 years and in 98.1% (n=261) after 9 years.  
 
Lipid Changes 
In the total cohort, 25.7% of patients received lipidlowering drugs during the study period, including 
22.7% of those not taking a PI and 39.8% of those taking a PI (p=0.004).  
 
Triglycerides (TG) decreased by 8% at 6 years (p=0.009), but showed a nonsignificant increase of 
3.6% at 9 years. With regard to HCV coinfection, TG decreased to a significantly greater extent in HCV+ 
patients than in HCVpatients (-17.6% vs -1.2%; p=0.024). TG levels were higher in pretreated patients 
(p<0.001), a significant decrease occurred only in pretreated patients (p<0.001), and the decrease (-16%, 
and -18.6% in patients not taking a PI) significantly differed from the levels in naïve patients (+9.3%, 
p<0.001) (Fig. 2).  
  
Total cholesterol increased at 9 years only in the subgroup of HCV- patients (+6.4%, p=0.006) and in 
naïve patients (+11.5%, p<0.001), with similar results in patients who were not receiving a PI.  
 
HDL-c data, collected in a subsample of 46 patients, showed an increase at 6 years (overall +19.7%, 
p<0.001) in both naïve and pretreated patients regardless of HCV status. No significant changes in LDL-c 
were observed in 40 patients with available follow-up data.  
 
At 6 years, the percentage of patients with HDL-c <1.03 mmol/L decreased from 33.7% to 17.5% 
(p=0.011), and the percentage with LDL-c >3.37 mmol/L decreased from 49.4% to 26.6% (p=0.004). 
Results were similar in patients who were not taking a PI.  
Liver Status Changes  
Overall, there were no differences from baseline in ALT values at 6 and 9 years. Nonetheless, 
although HCV+ patients had significantly higher ALT levels at baseline (0.75 μkat/L vs 0.40 μkat/L, 
p<0.001), transaminase decreases were greater in this group at 6 years: -3.6% vs +6.7% (p=0.047) and -
12.5% vs + 5.9% (p=0.026) in patients not receiving a PI. ALT decrease was greater in naïve patients: - 
10.5% vs +7.3% (p=0.020) at 6 years and -11.0% vs +8.5% (p=0.039) at 9 years (Fig. 2). A similar trend 




Fig. (3). CD4 counts versus HCV positive or negative status. 
 
  
As was expected, GGT increased by 78.1% and 117.3% at 6 and 9 years, respectively, regardless of PI 




Fig. (4). Percentage increase in hepatic variables vs HCV+ (all patients). 
Alkaline phosphatase (AP) decreased in the overall population at 6 and 9 years (-32.4% and -41.3%; 
both, p<0.001). AP levels were higher in HCV+ patients at baseline (p<0.001) and showed a greater 
decrease in this patient group at follow-up (-0.87 μkat/L [-36.3%] vs -0.63 μkat/L [-29.7%]; p=0.030) 
(Fig. 4). In addition, a larger AP decrease was seen in naïve patients at 6 and 9 years: -44.3% vs -28.3% 
(p=0.031) and -45.4% vs -34.0% (p=0.036), respectively (Fig. 2). The AP decrease was smaller, although 
still statistically significant, in patients receiving tenofovir in their ART regimens.  
 
The Fib-4 biochemical test was carried out to indirectly assess liver fibrosis. In HCV+ patients, Fib-4 
score did not change significantly after 6 (-1.72) or 9 years (-1.48), but it was significantly decreased in 
naïve patients compared to pretreated patients at these time points: -29.9% vs +14.7% (p<0.001) and -
22.8% vs +25.1% (p=0.003), respectively.  
 
In a subgroup of 89 patients, liver fibrosis was determined by FibroScan and/or biopsy; 51 patients 
(57.3%) presented at least moderate fibrosis (≥2 by biopsy or ≥7 by FibroScan). There were no 
differences in the ALT, AST, or GGT changes occurring in patients with or without fibrosis, but a greater 




After a median period of 9 years, 25.2% of patients initiating a nevirapine-containing regimen 
between 1998 and 2003, continued taking nevirapine. As it was not an objective of the study, we do not 
know the percentage of cases discontinuing the drug for reasons such as virologic failure, toxicity, lost to 
follow-up, or death. It has been well recognized that a proportion of patients stop nevirapine during the 
first months of therapy due to adverse effects, and that most patients tolerating nevirapine beyond this 
period of time will continue to receive it for the long term. It is difficult to compare our data with data 
from other studies with nevirapine or other drugs as there are no data with such long term follow up. A 
couple of studies [9, 10] have shown that lopinavir/ritonavir and efavirenz are effective and well tolerated 
after several years of follow-up. But these were prospective clinical trials in which patients are generally 
selected and closely follow up, making these populations different from the real life. As commented 
below, in the Eurosida cohort, after a median follow up time of 2.6 years, comparable discontinuation 
rates of about 50% were observed amongst nevirapine, efavirenz or lopinavir/ritonavir. Anyway, our data 
show that after a long period of time, a considerable proportion of patients initiating nevirapine will 
maintain the drug. Thus, it is clinically relevant to know the long term benefits and limitations of such 
therapy.  
 
In this long-term study, NVP-containing regimens were associated with an improvement in variables 
related to general health status, such as hemoglobin and albumin concentration and platelet counts, as 
well as increased CD4 counts, preserved liver function, and a favorable lipid profile. Our data are 
consistent with those of previous cohort studies assessing NVP regimens administered for a median of 6 
(n= 229) and 3.5 (n=613) years [11, 12]. The long-term safety of NVP with regard to the lipid profile and 
liver function in cohorts with a high prevalence (30%-60%) of HCV+ patients, was also reported in these 
articles. The large EUROSIDA study recently evaluated the outcomes of patients receiving regimens 
containing NVP, efavirenz, or lopinavir/ritonavir, and found that NVP durability was comparable to that 
of the other two regimens in routine clinical practice across Europe in patients who initially tolerated and 
virologically responded to therapy [13]. The greater discontinuation rate of NVP due to virologic failure 
was counterbalanced by a lower discontinuation rate due to toxicities or patient/physician choice [13].  
 
In the present study, a continuous increase in absolute CD4 count was observed, with a greater 
increase in naïve and HCV- patients, as was expected. These findings are in keeping with those of other 
long-term studies including a smaller number of patients who received lopinavir/r- and efavirenz-
containing regimens [6, 7].  
 
NVP use in HCV+ patients is controversial because liver toxicity is one of the main adverse effects 
occurring in patients receiving this drug [5]. Moreover, liver toxicity associated with the use of ARV 
drugs is usually somewhat higher in patients coinfected with HCV [4]. Most cases of NVP-associated 
hepatotoxicity appear during the first 2 to 3 months of therapy and manifest as a hypersensitivity reaction 
[14-17]. This clinical syndrome seems to be more frequent in patients with certain genetic markers [14], 
and is mainly driven by the presence of high CD4 counts (>400 cells/μL in men and >250 cells/μL in 
women), mostly in patients with detectable viral load [17-19]. When NVP is prescribed taking into 
consideration these CD4 cut-offs, as was done in the ARTEN study, the incidence of rash and liver 
toxicity is lower than has been previously described [20]. The published data are discordant regarding 
liver fibrosis in HIV/HCV+ patients receiving NVP or PIs [21, 22].Whereas Macías et al. [21] suggested 
that NVP regimens may be associated with faster progression of liver fibrosis in HIV/HCV patients when 
compared to PI regimens, Berenguer et al. [22] reported the opposite; that is, a reduction in fibrosis 
progression associated with NVP use compared to PIs and efavirenz. Of note, a recent study has 
suggested that in patients coinfected with HIV/HCV, interferon/ribavirin treatment is associated with a 
better response in those that have NVP in their ARV regimen [23].  
 
Our data show that the use of NVP in patients with HIV/HCV infection is relatively safe and provides 
long-term benefits when examining parameters negatively influenced by liver disease, such as 
hemoglobin, albumin and platelets, even in patients coinfected with HCV (40% of our cohort), and a 
percentage of them with abnormal transaminases at baseline. Moreover, despite this scenario, no 
worsening of transaminases occurred and there was a significantly more favorable change in ALT and 
AST in HCV+ patients and naïve patients, likely related to the beneficial effect of controlling HIV 
replication in HCV infection. The finding of a greater decrease in the Fib-4 score in naïve patients 
coincides with this observation. Concomitant use of a PI did not change the evolution of liver enzymes.  
 
It is well recognized that NVP is associated with an increase in GGT, and this was seen in our 
patients. As to AP, the notable decrease, mainly observed in naïve patients, HCV+ patients, and the 
subgroup with liver fibrosis, probably reflects an improvement in liver function in keeping with the 
transaminase results. Interestingly, patients receiving tenofovir had a significantly lower decrease in AP 
compared to patients receiving other drugs, suggesting that the known effect of tenofovir on bone AP 
increase counterbalanced the rise in total AP [24].  
 
NVP is recognized as one of the most lipid-friendly ART drugs [3,4,25-27], and it has been associated 
with better lipid profiles than other non nucleoside reverse transcriptase inhibitors, such as efavirenz. It 
also compares favorably with atazanavir, which has the best lipid profile among boosted Pis [22-23]. 
NVP is the ARV compound associated with the highest HDL-c concentrations, with increases reaching up 
to 40% in previous studies [25,26]. Our data further support these results, as is seen in the TG decrease 
and the percentage of patients with HDL-c and LDL-c levels below the cut-off recommended by the 
NCEP to initiate lipidlowering therapy. As was expected, lipid changes were more favorable in the 
pretreated patients, most of whom had received previous regimens with a worse lipid profile [26].  
 
This study has some limitations inherent to its retrospective design. One is that fibrosis evaluation by 
biopsy or FibroScan was only available in a subgroup of patients, limiting the information about the long-
term effect of NVP regimens on liver. The same was true for HDL-c and LDL-c levels, which were not 
routinely determined several years ago.  
 
It can be argued that the study does not provide information on the proportion of patients initiating a 
NVP regimen who had to discontinue the drug. In fact, we recognize that our patient population is biased 
because patients discontinuing nevirapine have been excluded. It is well known that a proportion of about 
13-20 % of patients initiating a nevirapine-containing regimen will stop the drug because of 
toxicities/virologic failure in the first year of follow-up, and this has been described in several papers [12, 
20]. However, our aim was to focus on the benefits obtained in several relevant clinical aspects occurring 
in patients initially tolerating NVP and maintaining the regimen in the long term. We believe our study 
offers valuable long-term information about NVP-containing regimens, in routine clinical practice.  
 
Few studies evaluating ART outcomes after such a long follow-up have been published to date. Our 
data reinforce the idea that nevirapine-containing regimens provide continuous benefits with regard to 
viral suppression and immune response, as well as good long-term tolerability, even in HCV-coinfected 
patients.  
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